Correlation Between Dupont De and Vaccibody
Can any of the company-specific risk be diversified away by investing in both Dupont De and Vaccibody at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Dupont De and Vaccibody into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Dupont De Nemours and Vaccibody As, you can compare the effects of market volatilities on Dupont De and Vaccibody and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dupont De with a short position of Vaccibody. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dupont De and Vaccibody.
Diversification Opportunities for Dupont De and Vaccibody
Poor diversification
The 3 months correlation between Dupont and Vaccibody is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Dupont De Nemours and Vaccibody As in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vaccibody As and Dupont De is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dupont De Nemours are associated (or correlated) with Vaccibody. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vaccibody As has no effect on the direction of Dupont De i.e., Dupont De and Vaccibody go up and down completely randomly.
Pair Corralation between Dupont De and Vaccibody
If you would invest 223.00 in Vaccibody As on October 22, 2024 and sell it today you would earn a total of 0.00 from holding Vaccibody As or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 0.8% |
Values | Daily Returns |
Dupont De Nemours vs. Vaccibody As
Performance |
Timeline |
Dupont De Nemours |
Vaccibody As |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Dupont De and Vaccibody Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Dupont De and Vaccibody
The main advantage of trading using opposite Dupont De and Vaccibody positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dupont De position performs unexpectedly, Vaccibody can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaccibody will offset losses from the drop in Vaccibody's long position.Dupont De vs. Roche Holding AG | Dupont De vs. Champions Oncology | Dupont De vs. Target 2030 Fund | Dupont De vs. The Monarch Cement |
Vaccibody vs. Molecular Partners AG | Vaccibody vs. MediciNova | Vaccibody vs. Anebulo Pharmaceuticals | Vaccibody vs. Champions Oncology |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Complementary Tools
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |